These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31566898)

  • 41. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016.
    Cowan AJ; Allen C; Barac A; Basaleem H; Bensenor I; Curado MP; Foreman K; Gupta R; Harvey J; Hosgood HD; Jakovljevic M; Khader Y; Linn S; Lad D; Mantovani L; Nong VM; Mokdad A; Naghavi M; Postma M; Roshandel G; Shackelford K; Sisay M; Nguyen CT; Tran TT; Xuan BT; Ukwaja KN; Vollset SE; Weiderpass E; Libby EN; Fitzmaurice C
    JAMA Oncol; 2018 Sep; 4(9):1221-1227. PubMed ID: 29800065
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data.
    Majer I; van de Wetering G; Polanyi Z; Krishna A; Gray E; Roy A
    Appl Health Econ Health Policy; 2017 Feb; 15(1):45-55. PubMed ID: 27550239
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression.
    Jung SH; Choi HJ; Shin MG; Lee SS; Hwang EC; Jung TY; Cho MS; Yang DH; Ahn JS; Kim YK; Kim HJ; Lee JJ
    Ann Hematol; 2016 Oct; 95(10):1645-51. PubMed ID: 27365142
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-Effectiveness of Novel Agents in Medicare Patients with Multiple Myeloma: Findings from a U.S. Payer's Perspective.
    Chen Y; Lairson DR; Chan W; Huo J; Du XL
    J Manag Care Spec Pharm; 2017 Aug; 23(8):831-843. PubMed ID: 28737990
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front-line regimens using the SEER-Medicare data.
    Goto D; Khairnar R; Yared JA; Yong C; Romanus D; Onukwugha E; Slejko JF
    Cancer Med; 2020 Jan; 9(2):626-639. PubMed ID: 31801177
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk of adverse events associated with front-line anti-myeloma treatment in Medicare patients with multiple myeloma.
    Chen Y; Lairson DR; Chan W; Du XL
    Ann Hematol; 2018 May; 97(5):851-863. PubMed ID: 29333596
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
    Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
    Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
    Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
    Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
    Varga C; Xie W; Laubach J; Ghobrial IM; O'Donnell EK; Weinstock M; Paba-Prada C; Warren D; Maglio ME; Schlossman R; Munshi NC; Raje N; Weller E; Anderson KC; Mitsiades CS; Richardson PG
    Br J Haematol; 2015 Jun; 169(6):843-50. PubMed ID: 26032514
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone.
    Kastritis E; Roussou M; Gavriatopoulou M; Kanellias N; Migkou M; Eleutherakis-Papaiakovou E; Ziogas DC; Fotiou D; Ntanasis-Stathopoulos I; Dialoupi I; Giannouli S; Tsirigotis P; Delimpasi S; Mparmparousi D; Spyropoulou-Vlachou M; Xirokosta A; Terpos E; Dimopoulos MA
    Blood Adv; 2019 Dec; 3(23):4095-4103. PubMed ID: 31821457
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States.
    Song X; Cong Z; Wilson K
    Curr Med Res Opin; 2016; 32(1):95-103. PubMed ID: 26488820
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
    Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
    Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Patterns and effectiveness of bortezomib use according to age in the VESUVE cohort.
    Grelaud A; Fourrier-Réglat A; Fitoussi O; Facon T; Jové J; Bénichou J; Robinson P; Marit G; Rouyer M; Moore N; Noize P;
    Leuk Lymphoma; 2016; 57(6):1349-54. PubMed ID: 26397802
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
    Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
    Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
    McCarthy PL
    J Natl Compr Canc Netw; 2013 Jan; 11(1):35-42. PubMed ID: 23307979
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis.
    Zhang S; Kulkarni AA; Xu B; Chu H; Kourelis T; Go RS; Wang ML; Bachanova V; Wang Y
    Blood Cancer J; 2020 Mar; 10(3):33. PubMed ID: 32144237
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Skeletal-Related Events in Patients With Multiple Myeloma: A Comprehensive Retrospective Cohort Study.
    Lee JY; Lee JH; Seo J; Kang M; Jung EH; Kim SA; Suh KJ; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Lee JS; Bang SM
    J Korean Med Sci; 2024 Jun; 39(22):e175. PubMed ID: 38859738
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
    Richardson PG; Laubach JP; Schlossman RL; Ghobrial IM; Redman KC; McKenney M; Warren D; Noonan K; Lunde L; Doss D; Colson K; Hideshima T; Mitsiades C; Munshi NC; Anderson KC
    Eur J Haematol; 2012 May; 88(5):446-9. PubMed ID: 22300348
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects.
    Ubels J; Sonneveld P; van Beers EH; Broijl A; van Vliet MH; de Ridder J
    Nat Commun; 2018 Jul; 9(1):2943. PubMed ID: 30054467
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients.
    Reneau JC; Asante D; van Houten H; Sangaralingham LR; Buadi FK; Lerman A; Herrmann J
    Am J Hematol; 2017 Feb; 92(2):E15-E17. PubMed ID: 27813147
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.